Xenon Pharmaceuticals Total Assets 2012-2022 | XENE

Xenon Pharmaceuticals total assets from 2012 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
Xenon Pharmaceuticals Annual Total Assets
(Millions of US $)
2021 $572
2020 $189
2019 $148
2018 $122
2017 $46
2016 $67
2015 $64
2014 $87
2013 $54
2012 $63
2011 $0
Xenon Pharmaceuticals Quarterly Total Assets
(Millions of US $)
2022-03-31 $558
2021-12-31 $572
2021-09-30 $264
2021-06-30 $275
2021-03-31 $291
2020-12-31 $189
2020-09-30 $199
2020-06-30 $211
2020-03-31 $237
2019-12-31 $148
2019-09-30 $99
2019-06-30 $106
2019-03-31 $115
2018-12-31 $122
2018-09-30 $130
2018-06-30 $65
2018-03-31 $38
2017-12-31 $46
2017-09-30 $46
2017-06-30 $54
2017-03-31 $61
2016-12-31 $67
2016-09-30 $73
2016-06-30 $56
2016-03-31 $61
2015-12-31 $64
2015-09-30 $70
2015-06-30 $77
2015-03-31 $79
2014-12-31 $87
2014-09-30 $54
2014-06-30 $0
2014-03-31 $0
2013-12-31 $0
2013-09-30 $0
2012-12-31 $63
2011-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.581B $0.018B
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.383B 9.82
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.475B 16.53
Biohaven Pharmaceutical Holding (BHVN) United States $9.944B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.681B 0.00
Emergent Biosolutions (EBS) United States $1.444B 6.18
Arcus Biosciences (RCUS) United States $1.389B 35.22
Myovant Sciences (MYOV) United Kingdom $0.879B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.509B 0.00
Gelesis Holdings (GLS) United States $0.362B 0.00
Zymeworks (ZYME) Canada $0.321B 0.00
Ambrx Biopharma (AMAM) United States $0.159B 0.00
Enzo Biochem (ENZ) United States $0.114B 23.50
SQZ Biotechnologies (SQZ) United States $0.093B 0.00